Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,187
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
CHF6001 DPI, CHF6001 DPI, Placebo to match CHF6001 DPI
Chiesi Farmaceutici S.p.A
Chronic obstructive pulmonary disease (COPD) and Chronic Bronchitis
1 trial -
IMP Placebo, Comparator Placebo, Seretide Evohaler 25 microgram/125 microgram per metered dose pressurised inhalation, suspension., CHF5993 pMDI (100) -152a
Chiesi Farmaceutici S.p.A
Uncontrolled Asthma
1 trial -
Multi-centre, Open-label Trial to Assess the SaFety, Pharmacodynamics, Efficacy and Pharmacokinetics of PegunigaLsidase Alfa in Patients from 2 Years to Less Than 18 Years of Age with Confirmed FabrY Disease (FLY)
Chiesi Farmaceutici S.p.A
Fabry's disease
1 trial -
Open Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegunigalsidase Alpha (PRX-102) 2 mg/kg Administered by Intravenous Infusion Every 4 Weeks in Patients with Fabry Disease
Chiesi Farmaceutici S.p.A
Fabry disease (α-galactosidase A deficiency)
1 trial -
Roflumilast (Daliresp®) 500µg, Roflumilast (Daliresp®) 250µg, CHF6001 DPI, Placebo to match CHF6001 DPI, CHF6001 DPI, Placebo to match Roflumilast (Daliresp®)
Chiesi Farmaceutici S.p.A
Chronic Obstructive Pulmonary Disease (COPD)
1 trial -
training kit, CHF1535 pMDI 100/6, CHF5993 pMDI-US
Chiesi Farmaceutici S.p.A
Chronic obstructive pulmonary disease (COPD)
1 trial -
0.9% sodium chloride aqueous solution for IV infusion
Chiesi Farmaceutici S.p.A
Idiopathic pulmonary fibrosis (IPF)
1 trial -
CHF5993 pMDI (100) -152a, CHF5993 pMDI HFA-152a, Trimbow 87 micrograms/5 micrograms/9 micrograms pressurised inhalation, solution
Chiesi Farmaceutici S.p.A
Mild to moderate asthma
1 trial -
CHF6001 DPI
Chiesi Farmaceutici S.p.A
Asthma
1 trial -
Cardiovascular safety assessment of Tanimilast in healthy volunteers
Chiesi Farmaceutici S.p.A
This is Phase I study to assess the effect on the heart rate (HR) and cardiovascular safety according to electrocardiographic monitoring (including QT and QTc intervals) of CHF6001(Tanimilast) administered with NEXThaler® device in healthy adult volunteers.
1 trial -
Comparison of the study drug CHF 1535 formulated with two different propellants to learn about drug levels in blood and safety after inhalation, with and without the use of the AeroChamber Plus® spacer, in healthy volunteers.
Chiesi Farmaceutici S.p.A
Asthma
1 trial -
Comparison of the study drug CHF 1535 formulated with two different propellants to learn about drug levels in blood and safety after inhalation, with and without the use of the Aerochamber Plus® spacer, in healthy volunteers.
Chiesi Farmaceutici S.p.A
Asthma and chronic obstructive pulmonary disease (COPD).
1 trial -
Effect of Erythromycin on the absorption, metabolism and elimination of CHF6001 in healthy volunteers
Chiesi Farmaceutici S.p.A
This study is a phase I trial to investigate the effect of inhibition of CYP3A4/5 by Erythromycin on the pharmacokinetics of CHF6001 in healthy volunteers.
1 trial -
Evaluation of safety, side effects and how the drug CHF6467 administrated via intranasal route is absorbed, modified and removed in healthy subjects.
Chiesi Farmaceutici S.p.A
Neonatal Hypoxic-Ischemic Encephalopathy (HIE), Neonatal Hypoxic-Ischemic Encephalopathy (HIE)
1 trial -
Evaluation of safety, side effects and how the inhaled drug CHF10073 is absorbed, modified and removed from the body when administered alone or in combination with itraconazole in male and female healthy adults
Chiesi Farmaceutici S.p.A
Pulmonary fibrosis
1 trial -
Evaluation of the CHF 5993 concentration in blood, after inhalation with two different devices, (NEXThaler® versus pMDI), with and without Aerochamber spacer device, in healthy volunteers.
Chiesi Farmaceutici S.p.A
Asthma
1 trial -
Evaluation of the effect of CHF6795 on the pharmacokinetics of midazolam, repaglinide and rosuvastatin in healthy subjects
Chiesi Farmaceutici S.p.A
Chronic cough
1 trial -
Not applicable
Chiesi Farmaceutici S.p.A
Non-cystic fibrosis bronchiectasis
1 trial -
Open-label, non-randomised, single-dose, one sequence, two-period, cross-over study to investigate the effect of inhibition of P-glycoprotein and breast cancer resistance protein transporters by cyclosporine on the pharmacokinetics of CHF6001 in healthy volunteers.
Chiesi Farmaceutici S.p.A
Chronic obstructive pulmonary disease
1 trial -
Fostair 200 microgram/6 microgram per actuation pressurised inhalation solution, Trimbow 87 micrograms/5 micrograms/9 micrograms pressurised inhalation, solution
Chiesi Farmaceutici S.p.A
Asthma
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources